How is Protonix 40 mg used to treat various gastrointestinal conditions. What are the recommended dosages for adults and children. What potential side effects should patients be aware of when taking Protonix.

Understanding Protonix and Its Active Ingredient Pantoprazole

Protonix is a brand name for the medication pantoprazole, which belongs to a class of drugs called proton pump inhibitors (PPIs). These medications work by reducing the amount of acid produced in the stomach. Pantoprazole is available in both oral and intravenous formulations, typically in strengths of 20 mg and 40 mg.

Is Protonix effective for treating various gastrointestinal conditions? Indeed, it is widely prescribed for conditions such as erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions, including Zollinger-Ellison syndrome. The drug’s ability to suppress stomach acid production makes it valuable in managing these disorders.

Dosage Guidelines for Protonix in Adult Patients

The dosage of Protonix varies depending on the condition being treated and the patient’s individual needs. Here are the general guidelines for adult patients:

Erosive Esophagitis Treatment and Maintenance

• Treatment: 40 mg orally once daily for 8 weeks
• Maintenance: 40 mg orally once daily

Can the treatment be extended if necessary? Yes, if patients are not healed after 8 weeks or if erosive esophagitis recurs, an additional 8-week course may be considered. However, controlled studies for maintenance therapy with the oral formulation did not extend beyond 12 months.

Gastroesophageal Reflux Disease (GERD)

• Oral: 40 mg once daily for 8 weeks
• Parenteral: 40 mg via IV infusion once daily for 7 to 10 days

When should IV treatment be discontinued? The intravenous formulation should be replaced with oral therapy as soon as the patient can tolerate it. It’s important to note that IV use has not been studied for periods longer than 10 days.

Zollinger-Ellison Syndrome and Other Hypersecretory Conditions

• Oral: 40 mg twice daily, with a maximum dose of 240 mg/day
• Parenteral: Initial dose of 80 mg IV every 12 hours, followed by a maintenance dose of 80 mg IV every 8 to 12 hours

Are there limitations to the parenteral treatment? Yes, the maximum daily dose for IV administration is 240 mg, and the maximum duration of therapy is 6 days. Patients should be transitioned to oral therapy as soon as possible.

Protonix Dosage for Pediatric Patients

Protonix is also used in pediatric patients for certain conditions. The dosage is based on the child’s weight:

• For children 5 years and older weighing 15 to less than 40 kg: 20 mg orally once daily
• For children 5 years and older weighing 40 kg or more: 40 mg orally once daily

How long can children take Protonix? The recommended duration of therapy for children is up to 8 weeks. Safety has not been established for treatment beyond this period in pediatric patients.

Special Dosing Considerations and Adjustments

While Protonix is generally well-tolerated, certain patient populations may require dosage adjustments:

Renal Impairment

Do patients with kidney problems need dose adjustments? Generally, no dosage adjustment is necessary for patients with renal impairment. However, as with all medications, these patients should be monitored closely.

Hepatic Impairment

For patients with severe hepatic impairment (Child-Pugh Class C), the maximum recommended dose is 20 mg daily. This precaution helps prevent potential accumulation of the drug in the system.

Elderly Patients

Are there special considerations for elderly patients? No dosage adjustment is generally required for elderly patients. However, as with all medications in this population, caution should be exercised, and the lowest effective dose should be used.

Potential Side Effects and Precautions

While Protonix is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

• Headache
• Diarrhea
• Nausea
• Stomach pain
• Vomiting
• Gas
• Dizziness
• Joint pain

Are there any serious side effects to be aware of? Yes, although rare, serious side effects can occur. These may include:

• Severe diarrhea
• Bone fractures
• Kidney problems
• Low magnesium levels
• Vitamin B12 deficiency
• Fundic gland polyps

Patients should be advised to seek medical attention if they experience any severe or persistent side effects.

Drug Interactions and Contraindications

Protonix can interact with other medications, potentially affecting their efficacy or increasing the risk of side effects. Some important interactions to consider include:

• Methotrexate
• Warfarin
• Clopidogrel
• HIV protease inhibitors
• Erlotinib
• Mycophenolate mofetil

Should patients inform their healthcare providers about all medications they’re taking? Absolutely. It’s crucial for patients to provide a complete list of all medications, including over-the-counter drugs, vitamins, and herbal supplements, to their healthcare provider before starting Protonix.

Long-term Use and Safety Considerations

While Protonix is effective for managing acid-related disorders, long-term use of proton pump inhibitors has been associated with certain risks. These may include:

• Increased risk of bone fractures
• Hypomagnesemia (low magnesium levels)
• Increased risk of Clostridium difficile infections
• Potential increased risk of kidney problems

How can patients mitigate these risks? Regular monitoring by a healthcare provider is essential for patients on long-term Protonix therapy. This may include periodic blood tests to check magnesium levels and assessment of bone density in high-risk patients.

Is it safe to stop Protonix abruptly? Patients should not discontinue Protonix without consulting their healthcare provider. Abrupt discontinuation may lead to rebound acid hypersecretion, potentially worsening symptoms.

Protonix in Special Populations

Certain populations require special consideration when using Protonix:

Pregnancy and Breastfeeding

Can Protonix be used during pregnancy? There are no adequate and well-controlled studies in pregnant women. Protonix should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Is it safe to use Protonix while breastfeeding? Pantoprazole and its metabolites are excreted in human milk. The clinical relevance of this finding is not known. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Geriatric Use

No dosage adjustment is needed based on age alone. However, elderly patients may be more sensitive to the effects of Protonix and may require closer monitoring.

Pediatric Use

The safety and effectiveness of Protonix have been established in pediatric patients aged 5 years and older for short-term treatment of erosive esophagitis associated with GERD. Use in patients under 5 years of age is not recommended due to lack of data.

Are there any long-term safety concerns for pediatric use? The long-term effects of Protonix in pediatric patients have not been established. Therefore, it’s important to use the lowest effective dose for the shortest duration necessary.

Pantoprazole Dosage Guide + Max Dose, Adjustments

Print

Save

Medically reviewed by Drugs.com. Last updated on Dec 26, 2022.

Applies to the following strengths: 40 mg; 20 mg

Usual Adult Dose for:

• Erosive Esophagitis
• Gastroesophageal Reflux Disease
• Zollinger-Ellison Syndrome
• Pathological Hypersecretory Conditions

Usual Pediatric Dose for:

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Erosive Esophagitis

Treatment: 40 mg orally once a day

• Duration of therapy: 8 weeks

Maintenance: 40 mg orally once daily

Comments:

• If patients are not healed after 8 weeks or erosive esophagitis (EE) recurs with the oral formulation, treatment for another 8 weeks may be considered.
• Controlled studies using the oral formulation for maintenance did not extend beyond 12 months.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Maintenance of healing of EE

Usual Adult Dose for Gastroesophageal Reflux Disease

Oral: 40 mg orally once a day

• Duration of therapy: 8 weeks

Parenteral: 40 mg via IV infusion once a day, given over at least 2 minutes OR over 15 minutes

• Duration of therapy: 7 to 10 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation has not been studied for longer than 10 days.
• Safety and efficacy for uses otherwise described (e.g., life-threatening gastrointestinal bleeds) are not available; however, use of this drug at 40 mg/day doses did not raise gastric pH to sufficient levels to contribute to the treatment of life-threatening conditions.
• If patients are not healed after 8 weeks with the oral formulation, treatment for another 8 weeks may be considered.

Uses:

• Short-term treatment of gastroesophageal reflux disease (GERD) in patients with a history of erosive esophagitis
• Reduction of relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD

Usual Adult Dose for Zollinger-Ellison Syndrome

Oral: 40 mg orally 2 times a day

• Maximum dose: 240 mg/day

Parenteral:

• Initial dose: 80 mg via IV infusion every 12 hours, given over at least 2 minutes OR over 15 minutes
• Maintenance dose: 80 mg via IV infusion every 8 to 12 hours, given over at least 2 minutes OR over 15 minutes
• Maximum dose: 240 mg/day
• Maximum duration of therapy: 6 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation for longer than 6 days and/or with doses higher than 240 mg has not been adequately studied.
• Patients may be vulnerable to increased acid production despite a short period of loss of effective inhibition.
• Patients given the oral formulation should be continued on therapy for as long as clinically necessary.

Uses:

• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
• Pathological hypersecretion conditions, including Zollinger-Ellison syndrome

Usual Adult Dose for Pathological Hypersecretory Conditions

Oral: 40 mg orally 2 times a day

• Maximum dose: 240 mg/day

Parenteral:

• Initial dose: 80 mg via IV infusion every 12 hours, given over at least 2 minutes OR over 15 minutes
• Maintenance dose: 80 mg via IV infusion every 8 to 12 hours, given over at least 2 minutes OR over 15 minutes
• Maximum dose: 240 mg/day
• Maximum duration of therapy: 6 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation for longer than 6 days and/or with doses higher than 240 mg has not been adequately studied.
• Patients may be vulnerable to increased acid production despite a short period of loss of effective inhibition.
• Patients given the oral formulation should be continued on therapy for as long as clinically necessary.

Uses:

• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
• Pathological hypersecretion conditions, including Zollinger-Ellison syndrome

Usual Pediatric Dose for Erosive Esophagitis

5 years and older:
15 to less than 40 kg: 20 mg orally once a day
40 kg and greater: 40 mg orally once a day
Duration of therapy: Up to 8 weeks

Comment: Safety has not been established in treatment beyond 8 weeks.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Short-term treatment of GERD in patients with a history of EE

Usual Pediatric Dose for Gastroesophageal Reflux Disease

5 years and older:
15 to less than 40 kg: 20 mg orally once a day
40 kg and greater: 40 mg orally once a day
Duration of therapy: Up to 8 weeks

Comment: Safety has not been established in treatment beyond 8 weeks.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Short-term treatment of GERD in patients with a history of EE

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

IV: Data not available

Oral: Doses over 40 mg/day have not been studied in patients with liver impairment. No adjustment recommended.

Dose Adjustments

CYP450 2C19 Poor Metabolizers:
Adults: No adjustment recommended.
Pediatric patients: Oral dose reductions should be considered.

Pathological Hypersecretion (including Zollinger-Ellison syndrome):

• Acid output target range: Less than 10 mEq/h

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component, substituted benzimidazoles, or any of the ingredients
• Patients receiving rilpivirine-containing products

Safety and efficacy of oral formulations have not been established in patients younger than 5 years. The IV formulation is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Tablet formulations should be swallowed whole, without crushing/chewing; tablets may be taken with or without food.
• For patients unable to swallow a 40 mg tablet, two 20 mg tablets may be taken; however, the 40 mg oral suspension packet formulation should not be divided to create two-20 mg dosages.
• Oral suspension/granule formulations should be taken on an empty stomach, preferably 30 to 60 minutes before a meal.
• The granule formulation may be sprinkled into applesauce or mixed into a small volume of either apple juice or orange juice and swallowed immediately. This drug may be mixed with apple juice and administered via nasogastric tube.

Storage requirements: The manufacturer product information should be consulted.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility: The manufacturer product information should be consulted.

General:

• This drug may be used concomitantly with antacids without affecting the absorption.
• Reflux symptoms may take 2 to 3 days to improve after initiation.
• Rapid acid control may be achieved within an hour at an IV dose of 160 mg.

Monitoring:

• HEPATIC: Liver function tests, especially in patients with impaired liver function
• METABOLIC: Magnesium levels, especially in patients taking other drugs that could result in hypomagnesemia or those on long-term therapy; Vitamin B12 levels, especially in patients on long-term therapy
• MUSCULOSKELETAL: Bone fractures, especially in patients at high-risk for osteoporosis-related events
• RENAL: Renal function tests

Patient advice:

• Advise patients to avoid taking concomitant proton pump inhibitors and/or h3 antagonists during treatment.
• If using this drug to treat H pylori, tell patients that it is important to complete the full regimen.
• Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, Clostridium difficile, or systemic cutaneous lupus erythematosus occur.
• Patients should be told that treatment may not provide immediate relief and that they should not take this drug for prophylaxis. Symptomatic relief may occur after 1 day of treatment, but patients should continue treatment for the full duration to achieve complete symptom control.
• Inform patients that this drug may cause dizziness or blurred vision, and they should avoid driving or operating machinery if these side effects occur.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

• Pantoprazole vs. omeprazole: What’s the difference between them?
• Can you take pantoprazole 40 mg twice a day?
• How long can I take pantoprazole?
• Does pantoprazole cause bloating?

More about pantoprazole

• Check interactions
• Compare alternatives
• Pricing & coupons
• Reviews (415)
• Drug images
• Side effects
• Patient tips
• During pregnancy
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Patient resources

• Drug Information
• Pantoprazole (Intravenous) (Advanced Reading)
• Pantoprazole (Oral) (Advanced Reading)
• Pantoprazole Delayed-Release Granules
• Pantoprazole Delayed-Release Tablets
• Pantoprazole Injection

Other brands

Protonix, Protonix IV

Professional resources

• Prescribing Information

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Dumping Syndrome
• Duodenal Ulcer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Pantoprazole Interactions Checker – Drugs.com

Print

Save

There are 163 drugs known to interact with
pantoprazole, along with
4 disease interactions.

Of the total drug interactions,
16 are major, 128 are moderate, and 19 are minor.

Does pantoprazole interact with my other drugs?

Enter other medications to view a detailed report.

• View all 163 medications that may interact with pantoprazole
• View pantoprazole disease interactions (4)

Most frequently checked interactions

View interaction reports for pantoprazole and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• Aspir 81 (aspirin)
• Aspirin Low Strength (aspirin)
• Benadryl (diphenhydramine)
• CoQ10 (ubiquinone)
• Crestor (rosuvastatin)
• Cymbalta (duloxetine)
• Eliquis (apixaban)
• Fish Oil (omega-3 polyunsaturated fatty acids)
• Flonase (fluticasone nasal)
• Lasix (furosemide)
• Lexapro (escitalopram)
• Lipitor (atorvastatin)
• Lyrica (pregabalin)
• Metoprolol Succinate ER (metoprolol)
• Metoprolol Tartrate (metoprolol)
• MiraLAX (polyethylene glycol 3350)
• Norco (acetaminophen / hydrocodone)
• Plavix (clopidogrel)
• ProAir HFA (albuterol)
• Singulair (montelukast)
• Symbicort (budesonide / formoterol)
• Synthroid (levothyroxine)
• Tylenol (acetaminophen)
• Vitamin B12 (cyanocobalamin)
• Vitamin C (ascorbic acid)
• Vitamin D2 (ergocalciferol)
• Vitamin D3 (cholecalciferol)
• Xanax (alprazolam)
• Xarelto (rivaroxaban)
• Zyrtec (cetirizine)

Pantoprazole disease interactions

There are 4 disease interactions with pantoprazole which include:

• C. diff
• liver disease
• bone fractures
• hypomagnesemia

Report options

Loading…

QR code containing a link to this page

More about pantoprazole

• pantoprazole consumer information
• Compare alternatives
• Pricing & coupons
• Reviews (415)
• Drug images
• Side effects
• Dosage information
• Patient tips
• During pregnancy
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Dumping Syndrome
• Duodenal Ulcer

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website